More on Array BioPharma (ARRY): FQ4 beats on a 9% Y/Y jump in total revenue. Net losses were...

|About: Array BioPharma Inc. (ARRY)|By:, SA News Editor

More on Array BioPharma (ARRY): FQ4 beats on a 9% Y/Y jump in total revenue. Net losses were pared significantly from the prior year period, as its top line was boosted by a jump in sales and its bottom line benefited from milestone payments from AMGN. Shares +6.6% AH.